In advanced breast cancer (mBC), single-agent administration showed modest clinical activity for programmed-death ligand 1 (PD-L1) inhibitors, with more favorable outcomes in the PD-L1 positive (+) population subset [18,19,20]. Here, CD274 is linked to breast carcinoma.